Treatment of multidrug-resistant gram-negative infections in children

Clinical Infectious Diseases

Volumn 58, Issue 10, 2014, Pages 1439-1448

  Hsu, Alice J ^a   Tamma, Pranita D ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

lactamases; Acinetobacter baumannii; AmpC ; lactamases; Carbapenemases; Extended spectrum ; Pseudomonas aeruginosa

Indexed keywords

AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ACINETOBACTER BAUMANNII; ANTIMICROBIAL THERAPY; BACTERICIDAL ACTIVITY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CRITICALLY ILL PATIENT; GRAM NEGATIVE INFECTION; HUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT OUTCOME; ADULT; CHILD; DRUG EFFECTS; ENTEROBACTERIACEAE; ENZYMOLOGY; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CHILD; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 84899830265     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu069     Document Type: Review

References (100)

1. Logan LK. Carbapenem-resistant Enterobacteriaceae: an emergingproblem in children. Clin Infect Dis 2012; 55:852-9.
2. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibioticresistantinfections: a call to action for the medical community fromthe Infectious Diseases Society of America. Clin Infect Dis 2008;46:155-64.
3. Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10×'20 Progress-development of new drugs active against gram-negative bacilli: anupdate from the Infectious Diseases Society of America. Clin InfectDis 2013; 56:1685-94.
4. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: aclinical update. Clin Microbiol Rev 2005; 18:657-86.
5. Dudley MN, Ambrose PG, Bhavnani SM, CraigWA, Ferraro MJ, JonesRN. Background and rationale for revised Clinical and LaboratoryStandards Institute interpretive criteria (breakpoints) for Enterobacteriaceaeand Pseudomonas aeruginosa: I. Cephalosporins and aztreonam.Clin Infect Dis 2013; 56:1301-9.
6. Marchaim D, Sunkara B, Lephart PR, et al. Extended-spectrumbeta-lactamase producers reported as susceptible to piperacillintazobactam,cefepime, and cefuroxime in the era of lowered breakpointsand no confirmatory tests. Infect Control Hosp Epidemiol2012; 33:853-5.
7. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and theinoculum effect in tests with extended-spectrum beta-lactamase- producingEnterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-54.
8. Zimhony O, Chmelnitsky I, Bardenstein R, et al. Endocarditis caused byextended-spectrum-beta-lactamase-producing Klebsiella pneumoniae:emergence of resistance to ciprofloxacin and piperacillintazobactamduring treatment despite initial susceptibility. AntimicrobAgents Chemother 2006; 50:3179-82.
9. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenemsversus alternative antibiotics for the treatment of bacteraemia due toEnterobacteriaceae producing extended-spectrum beta-lactamases: asystematic review and meta-analysis. J Antimicrob Chemother 2012;67:2793-803.
10. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Betalactam/beta-lactam inhibitor combinations for the treatment of bacteremiadue to extended-spectrum beta-lactamase-producing Escherichiacoli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167-74.
11. Pillay T, Pillay DG, Adhikari M, Sturm AW. Piperacillin/tazobactam inthe treatment of Klebsiella pneumoniae infections in neonates. Am JPerinatol 1998; 15:47-51.
12. Velaphi S,Wadula J, Nakwa F. Mortality rate in neonates infected withextended-spectrum beta lactamase-producing Klebsiella species andselective empirical use of meropenem. Ann Trop Paediatr 2009;29:101-10.
13. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepimetherapy for monomicrobial bacteremia caused by cefepime-susceptibleextended-spectrum beta-lactamase-producing Enterobacteriaceae:MIC matters. Clin Infect Dis 2013; 56:488-95.
14. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem- cilastatinfor treatment of nosocomial pneumonia in intensive care unit patients:a multicenter, evaluator-blind, prospective, randomized study. AntimicrobAgents Chemother 2003; 47:3442-7.
15. Hoban DJ, Lascols C, Nicolle LE, et al. Antimicrobial susceptibilityof Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolatesfrom hospitalized patients in North America and Europe:results from the SMART study 2009-2010. Diagn Microbiol InfectDis 2012; 74:62-7.
16. Perez F, Bonomo RA. Can we really use β;-lactam/β;-lactam inhibitorcombinations for the treatment of infections caused by extendedspectrumβ;-lactamase-producing bacteria? Clin Infect Dis 2012;54:175-7.
17. Wu UI, Chen WC, Yang CS, et al. Ertapenem in the treatment of bacteremiacaused by extended-spectrum beta-lactamase-producing Escherichiacoli: a propensity score analysis. Int J Infect Dis 2012; 16:e47-52.
18. Collins VL, Marchaim D, Pogue JM, et al. Efficacy of ertapenem fortreatment of bloodstream infections caused by extended-spectrumbeta- lactamase-producing Enterobacteriaceae. Antimicrob AgentsChemother 2012; 56:2173-7.
19. Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for thetreatment of urinary tract infections caused by extended-spectrumbeta- lactamase-producing bacteria in children. Scand J Infect Dis2011; 43:339-43.
20. Bassetti M, Righi E, Fasce R, et al. Efficacy of ertapenem in the treatmentof early ventilator-associated pneumonia caused by extendedspectrumbeta-lactamase-producing organisms in an intensive careunit. J Antimicrob Chemother 2007; 60:433-5.
21. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycinfor the treatment of multidrug-resistant, including extendedspectrumbeta-lactamase producing, Enterobacteriaceae infections: asystematic review. Lancet Infect Dis 2010; 10:43-50.
22. Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoinin the treatment of extended-spectrum beta- lactamaseproducingEscherichia coli-related lower urinary tract infection. Int JAntimicrob Agents 2012; 40:554-6.
23. Bradley JS, Jackson MA. The use of systemic and topical fluoroquinolones.Pediatrics 2011; 128:e1034-45.
24. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy fortreatment of infections with gram-negative bacteria. Clin MicrobiolRev 2012; 25:450-70.
25. Stein GE. Comparison of single-dose fosfomycin and a 7-day course ofnitrofurantoin in female patients with uncomplicated urinary tract infection.Clin Ther 1999; 21:1864-72.
26. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A reviewof its antibacterial activity, pharmacokinetic properties and therapeuticefficacy as a single-dose oral treatment for acute uncomplicated lowerurinary tract infections. Drugs 1997; 53:637-56.
27. Jodal U. The role of fosfomycin trometamol in the management of urinarytract infections in pediatrics. Infection 1992; 20(suppl 4):S317-20.
28. Clark CJ, Kennedy WA 2nd, Shortliffe LD. Urinary tract infection inchildren: when to worry. Urol Clin North Am 2010; 37:229-41.
29. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009;22:161-82, table of contents.
30. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinicalfeatures and emergence of antibiotic resistance during therapy. AnnIntern Med 1991; 115:585-90.
31. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factorsfor emergence of resistance to broad-spectrum cephalosporins amongEnterobacter spp. Antimicrob Agents Chemother 2001; 45:2628-30.
32. Choi SH, Lee JE, Park SJ, et al. Emergence of antibiotic resistance duringtherapy for infections caused by Enterobacteriaceae producingAmpC beta-lactamase: implications for antibiotic use. AntimicrobAgents Chemother 2008; 52:995-1000.
33. Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime fortreating AmpC beta-lactamase-producing Enterobacteriaceae. Clin InfectDis 2013; 57:781-8.
34. Livermore DM, Brown DF, Quinn JP, Carmeli Y, Paterson DL, Yu VL.Should third-generation cephalosporins be avoided against AmpCinducibleEnterobacteriaceae? Clin Microbiol Infect 2004; 10:84-5.
35. Goldstein FW. Cephalosporinase induction and cephalosporin resistance:a longstanding misinterpretation. Clin Microbiol Infect 2002;8:823-5.
36. Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC betalactamase-producing gram-negative bacilli: what are the alternatives tocarbapenems, quinolones and aminoglycosides? Int J AntimicrobAgents 2012; 40:297-305.
37. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health andeconomic outcomes of the emergence of third-generation cephalosporinresistance in Enterobacter species. Arch Intern Med 2002;162:185-90.
38. Boyle RJ, Curtis N, Kelly N, Garland SM, Carapetis JR. Clinical implicationsof inducible beta-lactamase activity in gram-negative bacteremiain children. Pediatr Infect Dis J 2002; 21:935-40.
39. Goossens H, Grabein B. Prevalence and antimicrobial susceptibilitydata for extended-spectrum beta-lactamase-and AmpC-producingEnterobacteriaceae from the MYSTIC Program in Europe and theUnited States (1997-2004). Diagn Microbiol Infect Dis 2005;53:257-64.
40. Jones RN, Sader HS, Fritsche TR, Pottumarthy S. Comparisons ofparenteral broad-spectrum cephalosporins tested against bacterial isolatesfrom pediatric patients: report from the SENTRY AntimicrobialSurveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007;57:109-16.
41. Kang CI, Pai H, Kim SH, et al. Cefepime and the inoculum effect intests with Klebsiella pneumoniae producing plasmid-mediated AmpCtypebeta-lactamase. J Antimicrob Chemother 2004; 54:1130-3.
42. Barnaud G, Benzerara Y, Gravisse J, et al. Selection during cefepimetreatment of a new cephalosporinase variant with extended- spectrumresistance to cefepime in an Enterobacter aerogenes clinical isolate.Antimicrob Agents Chemother 2004; 48:1040-2.
43. Fernandez-Cuenca F, Rodriguez-Martinez JM, Martinez-Martinez L,Pascual A. In vivo selection of Enterobacter aerogenes with reducedsusceptibility to cefepime and carbapenems associated with decreasedexpression of a 40 kDa outer membrane protein and hyperproductionof AmpC beta-lactamase. Int J Antimicrob Agents 2006; 27:549-52.
44. Negri MC, Baquero F. In vitro selective concentrations of cefepime andceftazidime for AmpC beta-lactamase hyperproducer Enterobactercloacae variants. Clin Microbiol Infect 1999; 5(suppl 1):S25-8.
45. Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in thetreatment of infections due to multiply resistant Enterobacter species.Clin Infect Dis 1996; 23:454-61.
46. Hilty M, Sendi P, Seiffert SN, et al. Characterisation and clinicalfeatures of Enterobacter cloacae bloodstream infections occurring ata tertiary care university hospital in Switzerland: is cefepime adequatetherapy? Int J Antimicrob Agents 2013; 41:236-49.
47. Adderson EE, Flynn PM, Hoffman JM. Efficacy and safety of cefepimein pediatric patients: a systematic review and meta-analysis. J Pediatr2010; 157:490-5, 495.e491.
48. Macdougall C. Beyond susceptible and resistant, part I: treatment ofinfections due to gram-negative organisms with inducible betalactamases.J Pediatr Pharmacol Ther 2011; 16:23-30.
49. Wolff MA, Young CL, Ramphal R. Antibiotic therapy for Enterobactermeningitis: a retrospective review of 13 episodes and review of theliterature. Clin Infect Dis 1993; 16:772-7.
50. Foster DR, Rhoney DH. Enterobacter meningitis: organism susceptibilities,antimicrobial therapy and related outcomes. Surg Neurol2005; 63:533-7; discussion 537.
51. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiellapneumoniae: (when) might we still consider treating with carbapenems?Clin Microbiol Infect 2011; 17:1135-41.
52. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, DaikosGL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae:an evolving crisis of global dimensions. Clin Microbiol Rev2012; 25:682-707.
53. Daikos GL, Markogiannakis A, Souli M, Tzouvelekis LS. Bloodstreaminfections caused by carbapenemase-producing Klebsiella pneumoniae:a clinical perspective. Expert Rev Anti Infect Ther 2012; 10:1393-404.
54. Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidalexposure for beta-lactams using prolonged and continuous infusionsin the pediatric population. Pediatr Blood Cancer 2009; 53:379-85.
55. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality inpatients with bloodstream infections caused by KPC-producing Klebsiellapneumoniae and impact of appropriate antimicrobial treatment.Clin Microbiol Infect 2011; 17:1798-803.
56. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality inbloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.Clin Infect Dis 2012; 55:943-50.
57. Hirsch EB, Tam VH. Detection and treatment options for Klebsiellapneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119-25.
58. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase(KPC) infections: a review of published case series and case reports.Ann Clin Microbiol Antimicrob 2012; 11:32.
59. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome ofbacteremia due to KPC-producing Klebsiella pneumoniae: superiorityof combination antimicrobial regimens. Antimicrob Agents Chemother2012; 56:2108-13.
60. Drusano GL. Antimicrobial pharmacodynamics: critical interactionsof 'bug and drug.' Nat Rev Microbiol 2004; 2:289-300.
61. Tamma PD, Jenh AM, Milstone AM. Prolonged beta-lactaminfusion for gram-negative Infections. Pediatr Infect Dis J 2011;30:336-7.
62. Roberts JA, Lipman J. Optimal doripenem dosing simulations in criticallyill nosocomial pneumonia patients with obesity, augmentedrenal clearance, and decreased bacterial susceptibility. Crit Care Med2013; 41:489-95.
63. Bulik CC, Nicolau DP. In vivo efficacy of simulated human dosing regimensof prolonged-infusion doripenem against carbapenemaseproducingKlebsiella pneumoniae. Antimicrob Agents Chemother2010; 54:4112-5.
64. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I.Efficacy and safety of intravenous infusion of doripenem versus imipenemin ventilator-associated pneumonia: a multicenter, randomizedstudy. Crit Care Med 2008; 36:1089-96.
65. Zobell JT, Kemper AL, Young DC. The use of doripenem in pediatriccystic fibrosis patients in case of meropenem shortages. Pediatr Pulmonol2013; 3:E48-E51.
66. Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenemresistantKlebsiella pneumoniae: the state of the art. Expert Rev AntiInfect Ther 2013; 11:159-77.
67. Tamma PD, Newland JG, Pannaraj PS, et al. The use of intravenouscolistin among children in the United States: results from a multicenter,case series. Pediatr Infect Dis J 2013; 32:17-22.
68. Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. Polymyxins:wisdom does not always come with age. Clin Infect Dis 2013;57:877-83.
69. Falagas ME, Kasiakou SK. Use of international units when dosingcolistin will help decrease confusion related to various formulationsof the drug around the world. Antimicrob Agents Chemother 2006;50:2274-5.
70. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibioticfor multidrug-resistant gram-negative bacterial infections. LancetInfect Dis 2006; 6:589-601.
71. Nation RL, Li J, Turnidge JD. The urgent need for clear and accurateinformation on the polymyxins. Clin Infect Dis 2013; 57:1656-7.
72. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistinadministration in critically ill patients: is this the right dosingstrategy? A preliminary study. Clin Infect Dis 2012; 54:1720-6.
73. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokineticanalysis of colistin methanesulfonate and colistin after intravenousadministration in critically ill patients with infections causedby gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-36.
74. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics ofcolistin methanesulfonate and formed colistin in critically ill patientsfrom a multicenter study provide dosing suggestions for various categoriesof patients. Antimicrob Agents Chemother 2011; 55:3284-94.
75. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME,Gilliam BL. Higher incidence of acute kidney injury with intravenouscolistimethate sodium compared with polymyxin b in critically illpatients at a tertiary care medical center. Clin Infect Dis 2013;57:1300-3.
76. Dara JS CL, Levi MH, Kreiswirth BN, Madan RP. Microbiological andgenetic characterization of carbapenem-resistant Klebsiella pneumoniaeisolated from pediatric patients. J Ped Infect Dis 2013; 1:1-5.
77. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis2006; 43:518-24.
78. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline:a systematic review and meta-analysis. J Antimicrob Chemother2011; 66:1963-71.
79. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significanceof the pharmacokinetic and pharmacodynamic characteristicsof tigecycline. Curr Drug Metab 2009; 10:13-21.
80. Food and Drug Administration. FDA Drug Safety Communication. FDAwarns of increased risk of death with IV antibacterial Tygacil (tigecycline)and approves new boxed warning. 2013. Available at: http://www.fda.gov/Drugs/DrugSafety/ ucm369580.htm. Accessed 9 October 2013.
81. Du XX, Fu Y, Yu YS. Tigecycline treatment of infection caused byKPC-producing Escherichia coli in a pediatric patient. Ann ClinMicrobiol Antimicrob 2013; 12:19.
82. Hurtado IC, Trujillo M, Restrepo A, Garces C, Tamayo C, Mesa JG.Experience with tigecycline compassionate use in pediatric patients infectedwith carbapenem resistant Klebsiella pneumoniae [in Spanish].Rev Chilena Infectol 2012; 29:317-21.
83. Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile oftigecycline in children aged 8 to 11 years with selected seriousinfections: a multicenter, open-label, ascending-dose study. ClinTher 2012; 34:496-507.e491.
84. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin:use beyond urinary tract and gastrointestinal infections. Clin InfectDis 2008; 46:1069-77.
85. Traunmuller F, Popovic M, Konz KH, Vavken P, Leithner A, JoukhadarC. A reappraisal of current dosing strategies for intravenous fosfomycinin children and neonates. Clin Pharmacokinet 2011; 50:493-503.
86. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin:evaluation of the published evidence on the emergence of antimicrobialresistance in gram-negative pathogens. J Antimicrob Chemother2012; 67:255-68.
87. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M,Falagas ME. Intravenous fosfomycin for the treatment of nosocomialinfections caused by carbapenem-resistant Klebsiella pneumoniae incritically ill patients: a prospective evaluation. Clin Microbiol Infect2010; 16:184-6.
88. Rossolini GM, Mantengoli E. Treatment and control of severe infectionscaused by multiresistant Pseudomonas aeruginosa. Clin MicrobiolInfect 2005; 11(suppl 4):17-32.
89. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenouscolistin versus intravenous colistin alone for the treatment ofventilator-associated pneumonia: a matched case-control study. ClinInfect Dis 2010; 51:1238-44.
90. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N,Thamlikitkul V. Randomized controlled trial of nebulized colistimethatesodium as adjunctive therapy of ventilator-associated pneumoniacaused by gram-negative bacteria. J Antimicrob Chemother 2010;65:2645-9.
91. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, FalagasME. Inhaled colistin as adjunctive therapy to intravenous colistinfor the treatment of microbiologically documented ventilator-associatedpneumonia: a comparative cohort study. Clin Microbiol Infect2010; 16:1230-6.
92. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases.Clin Microbiol Rev 2007; 20:440-58
93. Chu H, Zhao L,Wang M, Liu Y, Gui T, Zhang J. Sulbactam-based therapyfor Acinetobacter baumannii infection: a systematic review andmeta-analysis. Braz J Infect Dis 2013; 17:389-94.
94. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy fornosocomial infections caused by multidrug-resistant Pseudomonasaeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11.
95. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatmentof multidrug-resistant Acinetobacter baumannii ventilatorassociatedpneumonia (VAP) with intravenous colistin: a comparisonwith imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-8.
96. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. Whatis the efficacy and safety of colistin for the treatment of ventilator- associatedpneumonia? A systematic review and meta-regression. ClinInfect Dis 2012; 54:670-80.
97. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in thetreatment of multidrug-resistant Acinetobacter baumannii infections.J Antimicrob Chemother 2008; 61:417-20.
98. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin inthe treatment of nosocomial infections from multiresistant Acinetobacterbaumannii. J Infect 2006; 53:274-8.
99. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiogramsof multidrug-resistant clinical Acinetobacter baumannii:promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45:594-8.
100. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicincompared with colistin alone for the treatment of seriousinfections due to extensively drug-resistant Acinetobacter baumannii:a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57:349-58.